US · Healthcare · Biotechnology
EPS came in at 1.21 against a street estimate of 1.18 — a beat of 2.5%.
Analysts rate Royalty Pharma Plc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $65.38.
CONFIDENT RPRX delivered 25th consecutive quarter of strong growth with 6% portfolio receipts growth, 14% royalty receipts growth, and raised FY26 guidance. Deployed $1.1B in royalties including blockbuster TTR amyloidosis asset cliramitug. Maintains 14.2% ROIC and 20.1% ROIE. Q2 2026 China market development noted as early-stage opportunity; hiring underway, no material revenue contribution yet. Analysts probed competitive moat (CEO emphasized irreproducible portfolio assembled over decades), China geopolitical risk (early-stage; monitored but offshore structure limits exposure), and adverse selection in pharma co-funding (high diligence bar reinforced by recent deal quality). 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Morgan Stanley - Brokerage Accounts | 9.64% |
| Capital Research & Mgmt Co - Division 3 | 7.92% |
| BlackRock Inc | 6.25% |
| FMR Inc | 5.51% |
| State Street Corp | 2.77% |
| T. Rowe Price Associates, Inc. | 2.51% |
| Swedbank AB | 2.41% |
| Baillie Gifford & Co Limited. | 2.25% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the three months ended September 30, 2026, total income and other revenues were $690,103, up from $609,291 in the same period | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 Portfolio Receipts increased 9% to $890 million from $814 million. • Royalty Receipts rose 9% to $883 million | 2026-11-04 |
| Quarterly report · Q2 2026 ROYALTY PHARMA PLC – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total assets: $19.82 billion as of June 30, 2026 (vs. $19.62 billion December 31, 2025) | 2026-08-05 |
| Results announced · Q3 2026 ROYALTY PHARMA PLC – Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Portfolio Receipts: $773 million in Q2 2026, up 6% vs. $727 million in Q2 2025 • Roy | 2026-08-05 |
| Shareholder vote results · Q2 2026 ROYALTY PHARMA PLC - 8-K SUMMARY HEADLINE NUMBERS • Annual General Meeting held June 4, 2026 with 508,180,103 shares present or represented by proxy | 2026-06-04 |
| Material agreement · Q2 2026 ROYALTY PHARMA PLC (RPRX) - 8-K SUMMARY HEADLINE NUMBERS • Company entered into new $1.8 billion unsecured revolving credit facility on May 22, 2026 | 2026-05-28 |
| Quarterly report · Q1 2026 ROYALTY PHARMA PLC – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Assets: $19.8 billion (March 31, 2026) vs $19.6 billion (December 31, 2025) • Q1 | 2026-05-06 |
| Results announced · Q2 2026 ROYALTY PHARMA PLC – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Portfolio Receipts Q1 2026: $925 million, up 10% year-over-year ($839 million in Q | 2026-05-06 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.23 / share ex-date Nov 13, 2026 · pay Dec 10, 2026 | 2026-11-13 |
| Dividend | $0.23 / share ex-date Aug 14, 2026 · pay Sep 10, 2026 | 2026-08-14 |
| Dividend | $0.23 / share ex-date May 15, 2026 · pay Jun 10, 2026 | 2026-05-15 |
| Dividend | $0.23 / share ex-date Feb 20, 2026 · pay Mar 10, 2026 | 2026-02-20 |
| Dividend | $0.22 / share ex-date Nov 14, 2025 · pay Dec 10, 2025 | 2025-11-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Royalty Pharma Plc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.